[Core needle biopsy twice negative with rising PSA level. Does imaging help?].
In compliance with guidelines in cases of suspected prostate cancer, the standard approach involves transrectal ultrasound-guided systematic biopsies. Currently, according to the new S3 guideline for prostate cancer, 10-12 tissue samples should be collected per patient and session. If these primary specimens are negative, the number of multiple biopsies is generally increased in the second session to improve the diagnostic certainty with more biopsies. At the latest when the second core needle biopsy is performed in the presence of rising prostate-specific antigen (PSA) level, an attempt is made to minimize the risk of overlooking prostate cancer by further increasing the number of multiple biopsies in the sense of achieving saturation. In this instance, the number ranges from 6 to 143 tissue samples per session. Studies have provided evidence that after two systematic random biopsies the same number of additional random biopsies does not accomplish any essential improvement of diagnostic certainty. There are hardly any studies in the literature dealing with the role of imaging procedures after negative prostate biopsies. In a prospective clinical trial including 132 patients with an average of 12 negative previous biopsies, a dramatically high number of prostate carcinomas (66 of 132) could be detected with innovative imaging (1-6 targeted biopsies). This raises the question of how reliably multiple systematic biopsies can in fact exclude the presence of cancer. Thus, particularly after a negative series of multiple biopsies, it appears to be expedient to use specific imaging to enhance diagnostic certainty through quality. However, prospective clinical validation of the diverse innovative methods seems to be important before broad application.
Loch
T
T
Klinik für Urologie, Diakonissenkrankenhaus Flensburg, Lehrkrankenhaus der Christian-Albrechts-Universität, Knuthstrasse 1, 24939 Flensburg. lochti@diako.de
D001707:Biopsy, Needle / Q000706:statistics & numerical data*; D005858:Germany / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology*; D015203:Reproducibility of Results; D018570:Risk Assessment; D012307:Risk Factors; D012680:Sensitivity and Specificity
D017430:Prostate-Specific Antigen